On the recordJuly 21, 2014
I think the best way to do that is to ask the FDA or direct the FDA by legislation, or statute, or regulation changes, to allow that communication to go forward.
Source
congress.govEditor's note · Context
Bilirakis emphasizes the need for better communication with the FDA regarding pharmaceutical information.
Share
More from Gus Bilirakis
Apr 28, 2025
I appreciate the remarks of the gentlewoman from Illinois. I just want to say it has been great working with Representative Schakowsky on a number of bills over the years. She has really been very cooperative, and we are doing good things…
Apr 28, 2025
In closing, I commend Representative Wittman and Representative Castor for their good work on this particular bill, and I urge passage. I yield back the balance of my time. The SPEAKER pro tempore (Mr. Fulcher). The question is on the…
Dec 10, 2024
I am here to talk about my good friend, an outstanding leader, Chairwoman Rodgers. We are going to miss her. I am glad we can gather today, actually this evening, to recognize the outstanding leadership of Energy and Commerce Committee…
Apr 28, 2025
In closing, I urge a ``yes'' vote on this particular bill, and I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Florida (Mr. Bilirakis) that the House suspend the…
Other voices in this conversation
